News

Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible

We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the

Water management solutions aren't ordinarily the stuff of investor dreams, but that sure wasn't the case with Advanced Drainage Systems (NYSE: WMS) over the past five trading days. The stock was

A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global

Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter

Last year wasn't the best year for tech stocks, with many seeing drops into double-digit percentages. Luckily, 2023 has been much better. The tech-heavy Nasdaq Composite -- which tracks almost all

First Horizon (NYSE: FHN) saw its stock price rise 13.7% this week, as of Friday's opening bell, according to S&P Global Market Intelligence. The stock had been up as much as 14.7% during the week

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are

Shares of pipe maker Advanced Drainage Systems (NYSE: WMS) were up 8.8% through 11:15 a.m. ET on Thursday after the company reported a big earnings beat this morning.

Analysts had forecast that the

There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). The company beat earnings expectations for the first quarter as it has been slashing expenses, and recent clinical trials --

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Telecom giant AT&T (NYSE: T) is best known today as a leading wireless provider in the United States, but it's also investing heavily in fiber internet. The company now has 7.5 million fiber

Axsome Therapeutics (NASDAQ: AXSM) wowed investors late last year with strong data from a phase 3 study of AXS-05, its candidate treatment for Alzheimer's disease agitation. AXS-05 met its primary

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

Shares of clinical-stage metabolism specialist Viking Therapeutics (NASDAQ: VKTX) were up by 12.4%, on abnormally high volume, as of 3:12 p.m. ET Tuesday afternoon. The big gain came after the

Biotech stocks have been on a wild ride this year. For instance, the bellwhether SPDR S&P Biotech ETF (NYSEMKT: XBI) has been up by as much as 9%, and down by as much as 12%, during just the first

Shares of Summit Therapeutics (NASDAQ: SMMT) were down more than 13% on Tuesday. The biotech company's shares have been trending downward since it released first-quarter earnings late last week. On